publication venue for
- The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A Systematic Review 2023
- Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study.. 14:181. 2024
- Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial.. 14:155. 2024
- Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. 14:20. 2024
- Translocation t(14;16) in multiple myeloma: gangster or just part of the gang?. 14:7. 2024
- Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database. 13:181. 2023
- MRD negativity: considerations for older adults with multiple myeloma. 13:166. 2023
- Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database. 13:137. 2023
- Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. 13:129. 2023
- Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. 13:111. 2023
- Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study. 13:76. 2023
- Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy. 12:168. 2022
- Financial toxicity in hematological malignancies: a systematic review. 12:74. 2022
- Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study. 12:17. 2022
- Venetoclax for the treatment of translocation (11;14) AL amyloidosis. 10:55. 2020
- The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. 10:52. 2020
- Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. 8:106. 2018
- Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. 6:e404-e404. 2016